Corvus Q3 2026: $202.9M Cash Funds Operations Into Q2 2028 as Soquelitinib Trials Advance
CRVS sits 53% above its 52-week low of $6.39.
Summary
Corvus reported Q3 2026 results with $202.9 million in cash and securities funding operations into Q2 2028, while R&D spending nearly doubled year over year and the net loss widened to $20.3 million. All major soquelitinib data readouts sit in 2027.
Key Events · Earnings and Guidance · CRVS
-
Q3 2026 Results Reported
Net loss of $20.3 million for the three months ended September 30, 2026, versus $10.2 million a year earlier, on total operating expenses of $21.4 million.
-
Cash Runway Extended to Q2 2028
Cash, cash equivalents and marketable securities totaled $202.9 million at September 30, 2026, up from $56.8 million at December 31, 2025, including about $189.4 million in net proceeds from the January 23, 2026 financing.
-
R&D Spend Nearly Doubles
Research and development expense rose $9.3 million to $17.8 million from $8.5 million, driven by higher soquelitinib clinical trial and personnel costs.
-
Data Readouts Clustered in 2027
Angel Pharma's atopic dermatitis cohort 1 topline is anticipated in March 2027, hidradenitis suppurativa initial data in 1H 2027, and a Phase 2 asthma trial is planned to start by Q1 2027; the Phase 3 PTCL trial continues enrolling toward 150 patients.
Analysis · CRVS · Life Sciences
Corvus ended September 30, 2026 with $202.9 million in cash and securities, up from $56.8 million at year-end 2025 largely on the $189.4 million net proceeds from the January 2026 financing, and says that funds operations into the second quarter of 2028. That removes any near-term financing need, which matters because spending is climbing fast: R&D rose to $17.8 million in the quarter from $8.5 million a year earlier and the net loss widened to $20.3 million from $10.2 million. The pipeline readouts that justify the spend are all in 2027 — Angel Pharma's atopic dermatitis cohort 1 data in March 2027, hidradenitis suppurativa initial data in the first half of 2027, and an asthma Phase 2 trial starting by Q1 2027 — so the stock has a long stretch with no binary data event. The registrational Phase 3 PTCL trial continues enrolling toward 150 patients.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRVS was trading at $9.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $818.5M. The 52-week trading range was $6.39 to $26.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.